{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:02Z","timestamp":1790802422607,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117058","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:43:04Z","timestamp":1789688584000},"page":"117058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit"],"prefix":"10.1016","volume":"247","author":[{"given":"Matthieu","family":"Roulleaux Dugage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0105-0830","authenticated-orcid":false,"given":"Camille","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-4335","authenticated-orcid":false,"given":"Paul","family":"Matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Roussel-Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka\u00efssa","family":"Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-8359","authenticated-orcid":false,"given":"Madona","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rastislav","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hueso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-601X","authenticated-orcid":false,"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Pobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117058_bib1","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.117058_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117058_bib3","first-page":"125","article-title":"Advances in cancer immunology and cancer immunotherapy","volume":"21","author":"Voena","year":"2016","journal-title":"Discov Med"},{"key":"10.1016\/j.ejca.2026.117058_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ejca.2026.117058_bib5","first-page":"447","article-title":"Parsing clinical success rates","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.117058_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ijc.34181","article-title":"Eventual success rate and predictors of success for oncology drugs tested in phase I trials","volume":"152","author":"Haslam","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117058_bib7","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMc1803837","article-title":"Encouraging Trends in Modern Phase 1 Oncology Trials","volume":"378","author":"Chakiba","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117058_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117058_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.04.006","article-title":"Profile and outcome of cancer patients enrolled in contemporary phase I trials","volume":"188","author":"Alouani","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117058_bib10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/jnci\/djaa044","article-title":"Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved","volume":"112","author":"Zhang","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117058_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.117058_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-6-263","article-title":"Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital","volume":"6","author":"Ho","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.117058_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105331","article-title":"Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement","volume":"10","author":"Korakis","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117058_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12885-025-15311-5","article-title":"Patient characteristics related to screening failure in Phase I trials","volume":"26","author":"Ozaki","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.117058_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1634\/theoncologist.2013-0202","article-title":"Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit","volume":"18","author":"Fu","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117058_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117058_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105771","article-title":"Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations","volume":"10","author":"Segu\u00ed","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117058_bib18","doi-asserted-by":"crossref","first-page":"S764","DOI":"10.1016\/j.annonc.2024.08.1237","article-title":"1177P FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France","volume":"35","author":"Rouleau","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117058_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djaa144","article-title":"The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute","volume":"113","author":"Tolaney","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117058_bib20","unstructured":"Resilience Care I Digital Health Solutions. https:\/\/www.resilience.care\/fr (accessed Aug 27, 2026)."},{"key":"10.1016\/j.ejca.2026.117058_bib21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2024.42.16_suppl.1635","article-title":"Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center","volume":"42","author":"Torrado","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117058_bib22","unstructured":"Klineo - Trouver le bon essai clinique n\u2019a jamais \u00e9t\u00e9 aussi simple. https:\/\/www.klineo.com\/ (accessed Aug 27, 2026)."},{"key":"10.1016\/j.ejca.2026.117058_bib23","unstructured":"IQVIA | Transforming Life Sciences with Data, Technology & Human Science. https:\/\/www.iqvia.com\/ (accessed April 16, 2026)."},{"key":"10.1016\/j.ejca.2026.117058_bib24","unstructured":"Commissioner O of the. Project Optimus. FDA 2024; published online June 12. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus (accessed April 16, 2026)."},{"key":"10.1016\/j.ejca.2026.117058_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41571-023-00853-z","article-title":"Optimizing the FDA\u2019s Project Optimus: opportunities and challenges","volume":"21","author":"Rodney","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117058_bib26","article-title":"Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access","volume":"11","author":"Katsuya","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.ejca.2026.117058_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41416-018-0290-8","article-title":"Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre","volume":"119","author":"O\u2019Carrigan","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117058_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70203","article-title":"Targeting KRAS G12D: advances in inhibitor design","volume":"16","author":"Shi","year":"2025","journal-title":"Thorac Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:25Z","timestamp":1790800405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0959804926008403"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117058","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117058"}}